Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition
Open access

A Novel Nogo‐A Receptor Antagonist Peptide Impedes Alzheimer's Disease Pathology by Nogo‐A/NgR/ROCK Signaling Pathway

Zheng Zhang Hui-Min Tan Fang Shi Jia-Jia Dai Weilong Ding Junliang Li Yu-Ke Wang Rui Yang Xin-ke Xu Cheng Chen Fei Xiao Li-An Huang Xiaoyan Liu Rui Liao Li Yan
Aug 2026 · CNS Neuroscience & Therapeutics · Vol 32 · 0 citations · 58 references
Medicine

Abstract

To evaluate the therapeutic effects of NAP2, a novel NgR1 antagonist peptide, on Alzheimer's disease (AD) pathology and to determine whether inhibition of the Nogo‐A/NgR1/ROCK signaling axis can ameliorate neurodegenerative alterations in APP/PS1 mice.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Review Open access Aug 2026

GLP-1 receptor agonists for Alzheimer’s disease: Lessons from trials and translational challenges

Although GLP-1 receptor agonists show strong mechanistic rationale and supportive epidemiological signals for neuroprotection, large randomized trials in symptomatic AD have yielded negative clinical outcomes and do not support the therapeutic use in AD.

R. Stringhi, Alessandro Padovani, Elena Marcello · 0 citations
Open access Sep 2026

TMEM59 regulates microglial Aβ phagocytosis in a TREM2‐dependent manner and acts as a potential therapeutic target for Aβ amyloidosis

Microglia‐mediated clearance of amyloid beta (Aβ) is crucial for mitigating Alzheimer's disease (AD) progression, yet the molecular regulators of microglial phagocytosis remain incompletely understood.

Jian Meng, Yong Wang, Jing-Hui Wang et al. · 0 citations
Open access Sep 2026

TMEM106B is a selective modulator of TDP‐43 pathology in Alzheimer's disease

Co‐pathologies – including Lewy body, vascular, and TDP‐43 lesions – are common in Alzheimer's disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their influence on the development of specific co‐pathologies remains unclear.

Madison M. Reeves, Anna Calliari, Tiffany W. Todd et al. · 0 citations
Open access Aug 2026

Inhibition of Moesin and CD44 in stem cell‐derived neurons affects the pathological genetic signature associated with Alzheimer's disease

Using human induced pluripotent stem cells (hiPSCs)‐derived neurons, human induced pluripotent stem cells were assayed how reducing gene expression of MSN and CD44 affected amyloid beta secretion, tau phosphorylation, and transcriptional state.

Eiden H. Brewer, Charles A. Williams, Gregory A. Cary et al. · 0 citations
Open access Sep 2026

The Alzheimer's disease risk gene SORL1 is a regulator of excitatory neuronal function

Synaptic dysfunction is an early feature of Alzheimer's disease (AD) and proper localization of proteins involved in pre‐ and post‐synaptic composition is dependent on endosomal recycling and trafficking, cellular processes involving the AD risk gene sortilin‐related receptor 1 (SORL1).

C. Williams, Shannon E. Rose, Vera Stamenković et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.